VEGF-A

From WikiMD's Medical Encyclopedia

Revision as of 03:59, 30 March 2024 by Prab (talk | contribs) (CSV import)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Vascular Endothelial Growth Factor A (VEGF-A) is a protein that plays a critical role in the process of angiogenesis, which is the formation of new blood vessels from pre-existing vessels. This process is vital for the growth and development of tissues and organs, as well as in the healing of wounds. VEGF-A is part of the VEGF family, which includes several proteins, but VEGF-A is the most studied and significant member due to its specific actions in angiogenesis.

Function

VEGF-A acts primarily on endothelial cells, which line the interior surface of blood vessels. It binds to specific receptors on the surface of these cells, primarily VEGF receptor-1 (VEGFR-1) and VEGF receptor-2 (VEGFR-2). This binding initiates a series of signaling pathways that lead to endothelial cell proliferation, migration, and new blood vessel formation. VEGF-A also increases vascular permeability, allowing for the transport of nutrients and cells that can aid in tissue growth and repair.

Gene and Structure

The gene for VEGF-A is located on the human chromosome 6p21.1. The protein itself is a dimer, consisting of two identical or nearly identical subunits. There are several isoforms of VEGF-A, which arise due to alternative splicing of the mRNA transcript. These isoforms vary in their ability to bind to receptors and in their potency in inducing angiogenesis.

Clinical Significance

VEGF-A has been implicated in a variety of diseases, primarily those involving abnormal angiogenesis. In cancer, tumors can secrete VEGF-A to promote the formation of new blood vessels, a process known as tumor angiogenesis, which supplies the growing tumor with oxygen and nutrients. This has made VEGF-A a target for cancer therapy, with several drugs developed to inhibit its action.

In ophthalmology, abnormal angiogenesis in the eye, stimulated by VEGF-A, can lead to diseases such as diabetic retinopathy and age-related macular degeneration (AMD). Anti-VEGF therapies have been effective in treating these conditions by inhibiting the abnormal growth of blood vessels in the retina.

Therapeutic Applications

Several therapeutic agents targeting VEGF-A or its receptors have been developed and are used in the treatment of various diseases. These include monoclonal antibodies, soluble receptors, and small molecule inhibitors. The use of anti-VEGF therapies has become a standard treatment for certain types of cancer and eye diseases, demonstrating the critical role of VEGF-A in disease pathology and its potential as a therapeutic target.

Conclusion

VEGF-A is a pivotal factor in the regulation of angiogenesis, with significant implications for both physiological and pathological processes. Its role in disease has made it a key target for therapeutic intervention, leading to the development of treatments that have had a profound impact on diseases characterized by abnormal angiogenesis.

This article is a stub related to pharmacology. You can help WikiMD by expanding it!


Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes


Ad. Transform your life with W8MD's

GLP-1 weight loss injections special from $29.99 with insurance

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.